I've written about LDN twice before, but I feel the topic hasn't been exhausted. In recent years, low-dose naltrexone (LDN) has generated increasing interest as a potential method of supporting chronic pain treatment. Particular interest has emerged among patients with fibromyalgia, complex regional pain syndrome, autoimmune diseases, and neuropathies. It caught my attention too, though I haven't had the opportunity to try it myself.
Are we dealing with a breakthrough? Or another medication assigned greater capabilities than it actually possesses? The answer, as always in medicine, is more complex.
What is LDN?
Naltrexone is not a new drug. For many years it has been used at 50 mg doses to treat opioid and alcohol addiction. At that dose, it functions as an opioid receptor antagonist.
When the dose is reduced to typically 0.5–4.5 mg per day, it takes on a different role. Research suggests that at this range it may also affect microglia cells and neuroinflammatory processes, with effects that appear partially independent of classical opioid receptor action. This is why LDN is now treated not as "a smaller dose of the same drug" but as a distinct therapeutic concept being developed for chronic pain and diseases involving immune dysregulation.
Why it interested pain researchers
For many years, chronic pain was viewed primarily as a problem of tissue damage or abnormal signal conduction. Today we know the picture is far more complicated.
Growing attention is paid to microglia — immune cells of the nervous system. When nerve injury occurs or pain persists for a long time, microglia can enter a state of chronic activation, releasing proinflammatory substances that maintain nervous system hypersensitivity and perpetuate pain.
One hypothesis about LDN suggests the drug may modulate microglial activity and limit neuroinflammatory processes. Additionally, transient opioid receptor blockade may lead to increased activity of endogenous pain-relief systems, including endorphins. Though details of these mechanisms remain under investigation, they explain why LDN attracted interest from chronic pain specialists.
What does this mean for trigeminal neuropathy?
Painful post-traumatic trigeminal neuropathy most commonly develops after dental procedures, tooth extractions, implants, facial trauma, or other procedures causing nerve fiber damage. In some people, healing proceeds normally. In others, abnormal nervous system activity becomes established — resulting in burning, searing, stabbing, numbness, electric sensations, or touch hypersensitivity.
This is precisely why LDN's mechanism of action seems so interesting. It doesn't focus exclusively on suppressing pain perception. At least theoretically, it may influence processes maintaining chronic nervous system overreactivity.
What does the research actually show?
In 2025, the first case series was published examining LDN use in people with painful post-traumatic trigeminal neuropathy. The study came from a specialized facial pain center at Rutgers School of Dental Medicine and analyzed 12 patients with complete clinical data.
Authors reported that during follow-up visits, patients reported lower pain intensity than at baseline. No significant adverse effects were noted. The researchers concluded that LDN appears to be a safe and potentially effective option for chronic post-traumatic trigeminal neuropathy.
However, since only the abstract is publicly available, these results should be interpreted cautiously. The publication's very existence shows that the topic is beginning to attract attention from researchers specializing in facial pain.
Preclinical studies in animal models of trigeminal pain have shown reduction in allodynia — painful hypersensitivity to stimuli that shouldn't normally cause pain. These results support the biological plausibility of using LDN for neuropathic facial pain, though positive animal results don't always translate to human efficacy.
Broader analyses on chronic pain
Some reviews indicate the possibility of significant improvement in selected patient groups, particularly conditions with neuroinflammatory, neuropathic, or nociplastic components. In observational studies, many patients reported decreased pain, improved functioning, and reduced fatigue.
At the same time, more skeptical reviews note the small number of high-quality studies, small participant groups, and significant methodological variability. Some conclude that LDN's efficacy cannot yet be definitively confirmed for the entire chronic pain population.
There is no basis today to present LDN as treatment with certain effects. However, biological plausibility exists along with a growing number of clinical observations suggesting potential benefit for some patients.
Why does it help some but not others?
Chronic pain is not a homogeneous disease but an entire spectrum of disorders with potentially different biological mechanisms. Two people may receive the same diagnosis yet have partially different mechanisms responsible for their suffering.
If neuroinflammation and glial cell activation play a significant role in a specific person, they may theoretically benefit more from therapy targeting these processes. If other mechanisms dominate, the treatment response may be weaker.
Treatment in practice
One of the most frequently repeated features of LDN therapy is the need for patience. Unlike classical painkillers, effects usually don't appear after a few days. In many clinical observations, first noticeable benefits appeared only after several weeks. Sometimes full efficacy assessment required two or three months.
Treatment usually starts at very low doses (0.25–1 mg), then gradually increases until the best ratio of efficacy to tolerability is achieved. There is no single ideal dose for all patients.
Safety
One reason for LDN's popularity is its relatively favorable safety profile.
Most commonly reported side effects include vivid dreams, transient sleep disturbances, headaches, nausea, and mild gastrointestinal complaints. In most people these are mild and often resolve with dose reduction or slower titration.
The most important limitation concerns concurrent opioid use. Since naltrexone blocks opioid receptors, combining it with opioid medications requires special caution and should always occur under physician supervision.
Is LDN a first-line treatment?
No. Current guidelines for neuropathic pain treatment still rely primarily on gabapentin, pregabalin, carbamazepine, oxcarbazepine, and selected antidepressants.
LDN remains an off-label therapy, most commonly considered when standard treatment hasn't produced expected results or caused intolerable side effects.
This doesn't mean it's marginal — quite the opposite. The number of scientific publications dedicated to LDN continues to grow, and medical community interest is far greater today than a decade ago.
Final thoughts
If standard treatment hasn't brought expected improvement, a conversation with a specialist about LDN may be a reasonable step.
Pain is real. The fact that it isn't always visible on imaging doesn't mean it exists only in the imagination. Chronic neuropathic pain is a disease of the nervous system, not a lack of willpower.
And even if the road to improvement is long, knowledge is one of the tools that allows us to reclaim at least some control over it.
References:
Use of low-dose naltrexone in the management of posttraumatic trigeminal neuropathic pain: a retrospective case series — S. Ananthan, G. Heir, O. Korczeniewska — https://pubmed.ncbi.nlm.nih.gov/40590142/
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain — J. Younger, L. Parkitny, D. McLain — https://pubmed.ncbi.nlm.nih.gov/24526250/
Natalia — since 2014 I've been living with trigeminal nerve pain. I write in plain language, based on reliable sources and personal experience. Read my story →
Frequently Asked Questions
What is trigeminal neuralgia?
Trigeminal neuralgia is a chronic facial pain condition. It manifests as sudden, severe, usually one-sided pain attacks — often described as an electric shock. A single attack typically lasts from a few seconds to about two minutes.
What is the difference between neuralgia and neuropathy?
In simple terms: neuralgia primarily involves paroxysmal pain along a nerve, usually without loss of sensation. Neuropathy involves nerve damage that more often causes constant pain along with numbness and sensory loss.
Do regular painkillers help with neuropathic pain?
Usually not. Neuropathic pain responds poorly to paracetamol or anti-inflammatory drugs. Instead, medications that act on nerves are used, such as anticonvulsants like carbamazepine.
How does carbamazepine work for trigeminal neuralgia?
Carbamazepine is the first-line medication for trigeminal neuralgia. In a large proportion of patients, it provides effective pain control. It requires gradual dose adjustment and medical supervision.
What is the difference between gabapentin and pregabalin?
Both are anticonvulsant medications used for neuropathic pain. They differ in absorption and dosing characteristics. The choice and dosage should be determined by a physician.
Related Articles
Low Dose Naltrexone (LDN) — Patient Experiences and What the Research Shows
Low Dose Naltrexone (LDN) is attracting growing interest among patients with various conditions, including neuropathic pain. Although it is still used "off…
Low Dose Naltrexone (LDN) for Chronic Pain — What the Research Shows
In the search for effective, safe, and non-addictive methods of pain relief, low dose naltrexone (LDN) therapy is receiving increasing attention.
Gabapentin and Pregabalin for Trigeminal Neuralgia
Gabapentin and pregabalin are antiepileptic drugs commonly used to treat trigeminal neuralgia and other types of neuropathic pain. They work by calming ove…
Track your attacks, triggers, and medications — and show your doctor a clear picture of your condition.